인에이트바이오(INAB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.10 (-6.78%), 시가총액 $0.01B, 52주 범위 $0.12 ~ $4.17.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamm
인에이트바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
인에이트바이오의 현재 주가는 $1.10 (-6.78%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
인에이트바이오의 시가총액은 약 $0.01B입니다.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmu